Monitor the company's upcoming quarterly results for cash burn rate and progress on CHD program pre-commercial activities; the activist stake reduction one week prior suggests insider selling ahead of this dilutive raise.
VIR drugs
VIR drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vir Biotechnology priced an underwritten public offering of 15,000,000 shares of common stock at $10.00 per share, with gross proceeds of $150 million and expected net proceeds of approximately $140.4 million ($161.5 million if the underwriters' 30-day option for an additional 2,250,000 shares is fully exercised). The offering follows a recent activist stake reduction and a preliminary prospectus supplement filed one day earlier, and proceeds will fund pre-commercial activities for the CHD program, TCE oncology platform investments, and general corporate purposes. The 8.8% dilution (based on 171.3M shares outstanding) is a material negative event for existing shareholders.
Key Financial Metrics
Key Facts
- 15,000,000 shares offered at $10.00 per share, gross proceeds $150 million
- Underwriters have 30-day option for up to 2,250,000 additional shares
- Expected net proceeds of approximately $140.4 million ($161.5 million if option fully exercised)
- Underwriting discount of $0.60 per share; underwriters pay $9.40 per share
- Offering priced on November 12, 2026, expected to close November 16, 2026
- Proceeds to fund pre-commercial activities for CHD program, TCE oncology platform, and general corporate purposes
- Follows activist stake reduction (SC 13D/A filed Nov 6, 2026) and preliminary prospectus supplement (424B5 filed Nov 12, 2026)
Financial Impact
Dilution of approximately 8.8% based on 171.3M shares outstanding; gross proceeds of $150 million; net proceeds of approximately $140.4 million
Risk Factors
- 8.8% dilution to existing shareholders from the base offering
- Up to 10.1% dilution if the underwriters' option is fully exercised
- Activist investor ARCH Venture Fund IX reduced its stake by 0.5% just 7 days before this offering, potentially signaling lack of confidence
- Clinical-stage biotech with no approved products, raising cash through equity rather than revenue
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-461412 |
| Document: d156106d8k.htm | 0001193125-26-461412 |
| Document: d156106dex991.htm | 0001193125-26-461412 |
| Document: d156106dex992.htm | 0001193125-26-461412 |
| Document: d156106dex51.htm | 0001193125-26-461412 |
| Document: 0001193125-26-461412-index-headers.html | 0001193125-26-461412 |
| Document: 0001193125-26-461412-index.html | 0001193125-26-461412 |
| Document: 0001193125-26-461412.txt | 0001193125-26-461412 |
Track record
36 reports on VIR
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry $9.84 Now $9.58 +2.64% settles Nov 23
- Nov 13, 20263d ago 8-K Bearish 5/10 Viewing Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers